Please login to the form below

Not currently logged in
Email:
Password:

Novartis US appeals halt generic Famvir

Novartis says that a US court halted Israeli-based Teva's sale of a generic version of its Famvir genital herpes treatment

Novartis has said that that a US court has halted Israeli-based Teva's sale of a generic version of its Famvir (famciclovir) genital herpes treatment.

The Swiss-headquartered company said the injunction by the US Court of Appeals for the Federal Circuit was issued on 8 September, two days after a district court in New Jersey denied Novartis' motion to stop Israel's Teva from marketing its version of the drug.

The injunction requires Teva to submit a response by 11 September 2007, Novartis revealed in a company statement.

Novartis shares were down 0.4 per cent at CHF 63.25 (USD 53.27) on the Zurich stock exchange on 10 September 2007.

10th September 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...
clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...
What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...

Infographics